Peering into the pharmaceutical "pipeline": Investigational drugs, clinical trials, and industry priorities

Social Science and Medicine

Volumn 131, Issue , 2015, Pages 322-330

  Fisher, Jill A ^a   Cottingham, Marci D ^a   Kalbaugh, Corey A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

Cancer; Clinical trials; Global burden of disease; HIV AIDS; Mental illness; Pharmaceuticalization; Pharmaceuticals; R D

Indexed keywords

NEW DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER; DEVELOPING WORLD; DRUG DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS; MENTAL HEALTH; PHARMACEUTICAL INDUSTRY; RESEARCH AND DEVELOPMENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG COMPARISON; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; INVESTMENT; ACQUIRED IMMUNODEFICIENCY SYNDROME; DRUG APPROVAL; DRUG DESIGN; DRUG MISUSE; FOOD AND DRUG ADMINISTRATION; INTERNATIONAL COOPERATION; MENTAL DISORDERS; MORBIDITY; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RESEARCH; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; INTERNATIONALITY; MENTAL DISORDERS; MORBIDITY; NEOPLASMS; PRESCRIPTION DRUG OVERUSE; RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84925347795     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2014.08.023     Document Type: Article

References (75)

1. Abraham J. Pharmaceuticalization of society in context: theoretical, empirical and health dimensions. Sociology 2010, 44:603-622.
2. Abraham J., Davis C. Acomparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy. Soc. Sci. Med. 2005, 61:881-892.
3. Angell M. The Truth About the Drug Companies: How They Deceive Us and What to Do About It 2004, Random House, New York.
4. Applbaum K. Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster. Cult. Med. Psychiatry 2009, 33:185-215.
5. Applbaum K. Is marketing the enemy of pharmaceutical innovation?. Hastings Cent. Rep. 2009, 39:13-17.
6. Asberg C., Lum J. Pharm AD-ventures: a feminist analysis of the pharmacological imaginary of Alzheimer's disease. Body Soc. 2009, 15:95-117.
7. Barker K.K. Listening to Lyrica: contested illnesses and pharmaceutical determinism. Soc. Sci. Med. 2011, 73:833-842.
8. Bell S.E., Figert A.E. Medicalization and pharmaceuticalization at the intersections: looking backward, sideways and forward. Soc. Sci. Med. 2012, 75:775-783.
9. Biddle J. Lessons from the Vioxx debacle: what the privatization of science can teach us about social epistemology. Soc. Epistemol. 2007, 21:21-39.
10. Bishop F.L., Jacobson E.E., Shaw J.R., Kaptchuk T.J. Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos. Soc. Sci. Med. 2012, 74:767-774.
11. Busfield J. Globalization and the pharmaceutical industry revisited. Int. J. Health Serv. 2003, 33:581-605.
12. Busfield J. 'A pill for every ill': explaining the expansion in medicine use. Soc. Sci. Med. 2010, 70:934-941.
13. Campbell N.D., Lovell A.M. The history of the development of buprenorphine as an addiction therapeutic. Ann. N. Y. Acad. Sci. 2012, 1248:124-139.
14. Carpenter D.P. The political economy of FDA drug review: processing, politics, and lessons for policy. Health Aff. 2004, 23:52-63.
15. Casper M.J., Carpenter L.M. Sex, drugs, and politics: the HPV vaccine for cervical cancer. Sociol. Health Illn. 2008, 30:886-899.
16. Clarke A.E., Shim J.K., Mamo L., Fosket J.R., Fishman J.R. Biomedicalization: technoscientific transformations of health, illness, and U.S. biomedicine. Am. Sociol. Rev. 2003, 68:161-194.
17. Conrad P. The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders 2007, Johns Hopkins University Press, Baltimore.
18. Conrad P., Leiter V. From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation. Sociol. Health Illn. 2008, 30:825-838.
19. Davis C., Abraham J. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociol. Health Illn. 2011, 33:731-747.
20. Davis C., Abraham J. Rethinking innovation accounting in pharmaceutical regulation: a case study in the deconstruction of therapeutic advance and therapeutic breakthrough. Sci. Technol. Hum. Values 2011, 36:791-815.
21. DiMasi J.A., Feldman L., Seckler A., Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 2010, 87:272-277.
22. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J.Health Econ. 2003, 22:151-185.
23. Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health 2012, Duke University Press, Durham.
24. Ecks S. Global pharmaceutical markets and corporate citizenship: the case of Novartis' anti-cancer drug Glivec. BioSocieties 2008, 3:165-181.
25. Epstein S. Impure Science: AIDS, Activism, and the Politics of Knowledge 1996, University of California Press, Berkeley.
26. Etkin N.L. "Side effects": cultural constructions and reinterpretations of western pharmaceuticals. Med. Anthropol. Q. 1992, 6:99-113.
27. Fisher J.A. Medical Research for Hire: the Political Economy of Pharmaceutical Clinical Trials 2009, Rutgers University Press, New Brunswick.
28. Fishman J.R. Manufacturing desire: the commodification of female sexual dysfunction. Soc. Stud. Sci. 2004, 34:187-218.
29. Fishman J.R., Settersten R.A., Flatt M.A. In the vanguard of biomedicine? The curious and contradictory case of anti-ageing medicine. Sociol. Health Illn. 2010, 32:197-210.
30. Fox N.J., Ward K.J. Pharma in the bedroom . . . and the kitchen . . . the pharmaceuticalisation of daily life. Sociol. Health Illn. 2008, 30:856-868.
31. Goozner M. The $800 Million Pill: the Truth Behind the Cost of New Drugs 2005, University of California Press, Berkeley.
32. Greene J.A. Prescribing by Numbers: Drugs and the Definition of Disease 2007, Johns Hopkins University Press, Baltimore.
33. Greenslit N. Depression and consumption: psychopharmaceuticals, branding, and new identity practices. Cult. Med. Psychiatry 2005, 29:477-501.
34. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J.Biomed. Inform. 2009, 42:377-381.
35. Hart N., Grand N., Riley K. Making the grade: the gender gap, ADHD, and the medicalization of boyhood. Medicalized Masculinities 2006, 132-164. Temple University Press, Philadelphia. D. Rosenfeld, C.A. Faircloth (Eds.).
36. Healy D. Let Them Eat Prozac: the Unhealthy Relationship Between the Pharmaceutical Industry and Depression 2004, New York University Press, New York.
37. Healy D. Pharmageddon 2012, University of California Press, Berkeley.
38. Heger M. Clinical trials website struggles to serve as research data hub. Nat. Med. 2012, 18:837.
39. Howarth G. Death and Dying: a Sociological Introduction 2007, Polity, Cambridge, UK.
40. Kassirer J.P. On the Take: How America's Complicity with Big Business Can Endanger Your Health 2005, Oxford University Press, New York.
41. Kempner J. Gendering the migraine market: do representations of illness matter?. Soc. Sci. Med. 2006, 63:1986-1997.
42. King S. Pink Ribbons, Inc.: Breast Cancer and the Politics of Philanthropy 2006, U of Minnesota Press.
43. Lane C. Shyness: How Normal Behavior Became a Sickness 2008, Yale University Press, New Haven.
44. Lemmens T., Freedman B. Ethics review for sale? conflict of interest and commercial research review boards. Milbank Q. 2000, 78:547-584.
45. Lexchin J., Bero L., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. Br. Med. J. 2003, 326:1167-1170.
46. Light D., Lexchin J. Pharmaceutical R&D: what do we get for all that money?. Br. Med. J. 2012, 345:e4348.
47. The Risks of Prescription Drugs 2010, Columbia University Press, New York. D.W. Light (Ed.).
48. Light D.W., Lexchin J., Darrow J.J. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J.Law Med. Ethics 2013, 41:590-600.
49. Light D.W., Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties 2011, 6:34-50.
50. Loe M. The prescription of a new generation. Contexts 2008, 7:46-49.
51. Lowton K. Trials and tribulations: understanding motivations for clinical research participation amongst adults with cystic fibrosis. Soc. Sci. Med. 2005, 61:1854-1865.
52. Marshall B.L. "Hard science": gendered constructions of sexual dysfunction in the "Viagra age". Sexualities 2002, 5:131-158.
53. Maskovsky J. Do people fail drugs, or do drugs fail people?: the discourse of adherence. Transform. Anthropol. 2005, 13:136-142.
54. Morris N., Balmer B. Volunteer human subjects' understandings of their participation in a biomedical research experiment. Soc. Sci. Med. 2006, 62:998-1008.
55. Pammolli F., Magazzini L., Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 10:428-438.
56. Parexel Pharmaceutical R&D Statistical Sourcebook 2011/2012 2011, Parexel International Corporation, Waltham, MA.
57. Pecoul B., Chirac P., Trouiller P., Pinel J. Access to essential drugs in poor countries: a lost battle?. J.Am. Med. Assoc. 1999, 281:361-367.
58. Petryna A. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects 2009, Princeton University Press, Princeton.
59. PhRMA Response to Marcia Angell September 15, 2004.
60. PhRMA, n.d. What goes into the cost of prescription drugs? . . . and other questions about your medicines. In: PhRMA (Ed.). PhRMA, Washington, D.C.
61. Pollack A. ADrug's Second Act: Battling Jet Lag 2010, New York Times, New York.
62. Prosser H. Marvelous medicines and dangerous drugs: the representation of prescription medicine in the UK newsprint media. Public Underst. Sci. 2008, 19:52-69.
63. Race K. Pleasure Consuming Medicine: the Queer Politics of Drugs 2009, Duke University Press, Durham.
64. Riley J.C. Measuring morbidity and mortality. The Cambridge World History of Human Disease 1993, Cambridge University Press. K.F. Kiple (Ed.).
65. Saint Louis C. Long Lashes Without Prescription, But With Risks 2010, New York Times, New York.
66. Stacey C.L., Henderson S., MacArthur K.R., Dohan D. Demanding patient or demanding encounter?: A case study of a cancer clinic. Soc. Sci. Med. 2009, 69:729-737.
67. Starr P. The Social Transformation of American Medicine: the Rise of a Sovereign Profession and the Making of a Vast Industry 1982, Basic Books, New York, NY.
68. Sullivan D.A., Weitz R. Labor Pains: Modern Midwives and Home Birth 1988, Yale University Press, New Haven.
69. Timmermans S., McKay T. Clinical trials as treatment option: bioethics and health care disparities in substance dependency. Soc. Sci. Med. 2009, 69:1784-1790.
70. Watkins E.S. Testosterone and the pharmaceuticalization of male aging. Aging Men, Masculinities and Modern Medicine 2013, Routledge, New York. A. Kampf, B.L. Marshall, A. Petersen (Eds.).
71. WHO - World Health Organization Global Status Report on Noncommunicable Diseases 2010, (Geneva).
72. WHO - World Health Organization The Top 10 Causes of Death 2011.
73. Williams S.J., Gabe J., Davis P. The sociology of pharmaceuticals: progress and prospects. Sociol. Health Illn. 2008, 30:813-824.
74. Williams S.J., Martin P., Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociol. Health Illn. 2011, 33:710-725.
75. Williams S.J., Seale C., Boden S., Lowe P., Steinberg D.L. Waking up to sleepiness: modafinil, the media and the pharmaceuticalisation of everyday/night life. Sociol. Health Illn. 2008, 30:839-855.